IMS 2022 | ALTITUDE: venetoclax, daratumumab, and dexamethasone in systemic AL amyloidosis with t(11;14)
Sandy Wong
• 26 Aug 2022
Sandy Wong, MD, University of California, Los Angeles, CA, comments on the design and inclusion criteria of the ALTITUDE study (NCT05486481), which is a Phase I/II study that will evaluate the combination of venetoclax, daratumumab, and dexamehtasone in patients with systemic AL amyloidosis who carry translocation (11;14) and who have received one prior line of therapy. This study is expected to start in January 2023. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
